文献速递肝病

肝移植中的肝肾综合征-急性肾损伤

Hepatorenal Syndrome-Acute Kidney Injury in Liver Transplantation.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-01-01

本文综述肝肾综合征(HRS)更名为HRS-急性肾损伤(AKI)后的管理要点,指出HRS是肝硬化门脉高压所致血管扩张及炎症反应加剧的复杂表现,预后差,常见于感染尤其自发性细菌性腹膜炎。文章讨论HRS对等待肝移植患者管理的影响、预防策略及近期治疗进展在肝移植背景下的意义。

要点

  • 肝硬化患者出现AKI时,应将HRS-AKI列为重要鉴别诊断。
  • 就诊时应停用可能触发药物,并排除肾前性AKI、内在肾病及结构性尿路病变。
  • 白蛋白扩容联合血管收缩药物是治疗HRS-AKI最有效的内科手段。

核心结论

  • 肝移植通常被认为是HRS最有效的治疗,但及时为所有需要者提供该救命治疗的 logistics 障碍是主要限制。
  • 特利加压素已被显示可使相当比例接受治疗者的HRS-AKI逆转,并可能提高肝移植患者生存率及摆脱肾脏替代治疗。

研究设计与样本

  • 本文为综述,回顾HRS对等待肝移植患者管理的影响、预防策略及近期治疗进展在肝移植背景下的主要意义。

主要发现

  • HRS是肝硬化门脉高压所致慢性血管扩张变化并因炎症反应加剧的复杂反应,对肝硬化患者预示不良预后。
  • 该综合征常见于感染背景,尤其是自发性细菌性腹膜炎。
  • 白蛋白扩容联合血管收缩药物对抗 underlying 内脏血管扩张,是管理该过程最有效的内科方式。

关键数值与推荐

  • 就诊时必须停用潜在触发药物,并排除肾前性AKI、内在肾脏疾病及结构性尿路病变作为损伤原因。
  • 特利加压素已被显示可使相当比例接受治疗者的HRS-AKI逆转。

临床怎么用

  • 肝硬化患者出现AKI时,HRS-AKI须在鉴别诊断中高度考虑。
  • 就诊时应停用潜在触发药物,并排除肾前性AKI、内在肾病及结构性尿路病变。
  • 使用白蛋白扩容联合血管收缩药物治疗 underlying 内脏血管扩张。
  • 肝移植通常被认为是HRS最有效的治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatorenal syndrome (HRS) is a serious complication of cirrhosis. HRS nomenclature has recently changed to HRS-AKI (acute kidney injury). HRS is a complex response to chronic vasodilatory changes brought about by portal hypertension and exacerbated by inflammatory responses that portends poor prognosis to patients with cirrhosis. This syndrome is commonly seen in the setting of infections, particularly spontaneous bacterial peritonitis. Because of the frequency of renal injury in the patient with cirrhosis, HRS-AKI has to be considered high in the differential diagnosis of AKI. Discontinuation of potential triggering agents and elimination of pre-renal AKI, intrinsic renal disease, and structural uropathy as causes of injury are imperative on presentation. Volume expansion with albumin and vasoconstrictive drugs to counteract the underlying splanchnic vasodilation constitutes the most effective medical modality to manage this process. Although the most effective therapy is generally considered to be liver transplantation (LT), the logistic barriers of offering this life-saving therapy on time to all needing it is a major limitation. Terlipressin has been shown to reverse HRS-AKI in a significant proportion of those treated and consequently can lead to increased LT patient survival and freedom from renal replacement therapy. We will review the impact of HRS on the management of patients awaiting LT, present strategies to prevent this significant complication, and discuss major implications of recent therapeutic advances in the setting of LT.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Lizaola-Mayo B, Vargas HE. Hepatorenal Syndrome-Acute Kidney Injury in Liver Transplantation. Clin Gastroenterol Hepatol. 2023. PMID: 37625863. doi:10.1016/j.cgh.2023.06.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。